Current Partners

MERCK CIE/EMD MILLIPORE

Schaffhausen, Switzerland: A division of EMD-Millipore, Merck Cie, has developed a proprietary process to manufacture the patented structurally-specific lipid used in Versamune®. Merck Cie has granted PDS Biotechnology an exclusive worldwide commercial license to utilize the chiral lipid in immunotherapies and vaccines.  Merck Cie provides the lipid manufactured under cGMP conditions for use in PDS Biotechnology’s products.

Merck KGaA

Darmstadt, Germany: PDS has granted Merck KGaA an exclusive worldwide license to utilize PDS Biotechnology’s novel Versamune® platform in selected next-generation cancer immunotherapies.